Resources: Gene Patenting
In June 2013, the Supreme Court held that naturally occurring gene sequences and their naturally occurring derivatives are not patent eligible. This link includes a brief summary of the case, as well as the full opinion and links to the audio of oral argument.
Shortly after the Supreme Court ruling in Myriad, this article summarizes the implications of the decision and its influence on the biotech industry.
This article addresses misconceptions regarding gene patents and whole-genome sequencing.
In this case, the Supreme Court held that the processes involved in a test for proper dosages of drug treatments are unpatentable laws of nature.
This article discusses the implications of the Mayo v. Prometheus decision, including its potential impact on gene patents. It also suggests possible routes that Congress can take on the issue of gene patenting.